Wednesday 18th November 2020
|Text too small?|
AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announces the establishment of a new subsidiary in Ireland, to drive the growth of the company’s products in Europe. It also announces new licensing, distribution and supply agreements for:
• Maxigesic IV® in Ireland, and Thailand
• Maxigesic tablets in Greece, Pakistan and Ecuador
AFT Managing Director Dr Hartley Atkinson said the decision to open a European representative office is a response to the ongoing growth in demand in the region for its Maxigesic product range.
“Maxigesic IV® has now been submitted for registration in 27 European countries and 17 of these have been approved. As the number of registrations increases, so too will the need for AFT to provide local support to Licensees and Distributors such as regulatory services. Eddie is well placed to oversee this support and ensure AFT makes the most of the significant opportunities we see in the region.”
According to an independent report by DelveInsight* published earlier this year, Maxigesic in its various dose forms has the potential to generate sales of more than $80 million across Europe’s major markets and the UK by 2028.
“We are also delighted to have secured agreements for Maxigesic IV® distribution with Ireland’s Jed Pharmaceuticals for Ireland, along with Alliance Pharma in Thailand. We have concluded licensing agreements with Switzerland’s Acino for Maxigesic oral dose forms in Ecuador and Greek’s market leading Elpen Pharmaceuticals, along with distribution agreements with the Karachi-based Excel Healthcare Laboratories for Pakistan,” Dr Atkinson said.
See the links below for more details:
No comments yet
Air New Zealand Limited (NZX: AIR) Awarded Second Phase of International Cargo Flights
Me Today Limited (NZX: MEE) Results for the Six Months Ended 30 September 2020
PaySauce Limited (NZX: PYS) FY2021 Half Year Result and Interim Report
General Capital Limited (NZX: GEN) Announces Solid Growth Despite Covid-19
Moa Group Limited (NZX: MOA) Announces Half-year Results
Evolve Education Group Limited (NZX: EVO) Interim Results for Six Months Ended 30 September 2020
IPO Offer: New Zealand Rural Land Co
Infratil Limited 6-year Infrastructure Bonds
Genesis Energy Limited (NZX: GNE) Undertaking Strategic Review of Kupe
Plexure Group Limited (NZX: PX1) NZ$5 Million Share Purchase Plan Closes